Canrenone
Back to searchMolecule Structure
Scientific Name
Canrenone
Description of the Drug
Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB12221
http://www.drugbank.ca/drugs/DB12221
Brand Name(s)
Not Available
Company Owner(s)
Not Available
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Mineralocorticoid receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1994 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL19560 | |
| Human Metabolome Database | HMDB0003033 | |
| DrugBank | DB12221 | |
| PubChem: Thomson Pharma | 14875687 | 14851493 |
| PubChem | 13789 | |
| Mcule | MCULE-8218872905 | |
| Nikkaji | J7.205B | |
| EPA CompTox Dashboard | DTXSID3045930 | |
| DrugCentral | 478 | |
| Brenda | 59425 | |
| ChemicalBook | CB0147626 | |
| rxnorm | CANRENONE | |
| ChEBI | 135445 | |
| ZINC | ZINC000003881648 |
